楷莱在淋巴瘤领域的必威体育精装版进展.ppt

* Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: Discussion Points: Additional Information: * Objective: To determine 安全性 of substituting PLD in R-CHOP regimen (DR-COP) in B-细胞 NHL 患者 Discussion Points: 所有患者were treated with PLD 40mg/m2, 环磷酰胺, 750 mg/m2; 长春新碱 2.0 mg; all given IV on 第1天. 泼尼松, 100 mg was given orally on 第1-5天. Rituxan, 375 mg/m2 IV 第1天was added to the regimen starting cycle 2. Che月therapy 疗程 were repeated every 21 days. 52 患者 had 分级III (n= 9) or IV (n= 43) 疾病 PPE 3 患者 experienced 3 级 毒性 – 0 患者 4 级. PFS: mean probability as 预估的 by KM analysis is 56% surviving at 3 岁 Additional Information: 3 级-4 不良反应’s do not present all 不良反应’s from abstract 和poster, but review 不良反应’s of importance to PLD * Objective: Discussion Points: Additional Information: * Objective: To determine 安全性 of substituting PLD in R-CHOP regimen (DR-COP) in B-细胞 NHL 患者 Discussion Points: 所有患者were treated with PLD 40mg/m2, 环磷酰胺, 750 mg/m2; 长春新碱 2.0 mg; all given IV on 第1天. 泼尼松, 100 mg was given orally on 第1-5天. Rituxan, 375 mg/m2 IV 第1天was added to the regimen starting cycle 2. Che月therapy 疗程